A phase I study of CHOP [cyclophosphamide, vincristine, doxorubicin, prednisone] and Campath-1H [alemtuzumab] in previously untreated aggressive T/NK-Cell lymphomas.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
Indications Diffuse large B cell lymphoma; T-cell lymphoma
Focus Adverse reactions

19 Jan 2017 Status changed from active, no longer recruiting to completed.
02 Dec 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
16 Nov 2011 Planned End Date changed from 1 May 2008 to 1 Mar 2013 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com